Intellipharmaceutics International Inc. announced that it has commenced a research and development program of pharmaceutical cannabidiol (“CBD”) based products. The Company believes that its current technology platforms could find use in cannabidiol therapeutics. To this end the Company has filed provisional patent applications with the United States Patent and Trademark Office pertaining to the delivery and application of cannabinoid-based therapeutics. The patent filings, together with certain of the Company’s already issued drug delivery patents, are intended to form the basis of the development of a pipeline of novel controlled-release product candidates with CBD as the main active ingredient.